Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer

McMeekin, Scott; Dizon, Don; Barter, James; Scambia, Giovanni; Manzyuk, Lyudmila; Lisyanskaya, Alla; Oaknin, Ana; Ringuette, Sarah; Mukhopadhyay, Pralay; Rosenberg, Julie; Vergote, Ignace

doi:10.1016/j.ygyno.2015.04.026

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer

Author:

McMeekin, Scott

Dizon, Don ; Barter, James ; Scambia, Giovanni ; Manzyuk, Lyudmila ; Lisyanskaya, Alla ; Oaknin, Ana ; Ringuette, Sarah ; Mukhopadhyay, Pralay ; Rosenberg, Julie ; Vergote, Ignace

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, Endometrial cancer, Ixabepilone, Second-line, Advanced, Metastatic, Single-agent, Chemotherapy, GYNECOLOGIC-ONCOLOGY-GROUP, BREAST-CANCER, CARCINOMA, CHEMOTHERAPY, RECURRENT, CISPLATIN, ANTHRACYCLINE, CAPECITABINE, RESISTANT, EFFICACY, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Doxorubicin, Endometrial Neoplasms, Epothilones, Female, Humans, Middle Aged, Paclitaxel, Survival Rate, 1112 Oncology and Carcinogenesis, 1114 Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis, 3215 Reproductive medicine

Abstract:

The purpose of this multicenter, open label, randomized phase III study was to determine whether ixabepilone resulted in improved overall survival (OS) compared with commonly used single-agent chemotherapy (doxorubicin or paclitaxel) in women with locally advanced, recurrent, or metastatic endometrial cancer with at least one failed prior platinum-based chemotherapeutic regimen.